Effect of Topical Anesthesia on Hemodynamics During the Induction Period in Patients Undergo Cardiac Surgery.

Sponsor
Qianfoshan Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT04744480
Collaborator
(none)
96
1
2
13.7
7

Study Details

Study Description

Brief Summary

The aim of the induction is to decrease stress response of endotracheal intubation. It is also important to keep hemodynamics stable during and after the induction period. Previous studies have shown that topical anesthesia can provide excellent superior supraglottic and subglottic local anesthetic effects and can significantly reduce the dosage of intravenous anesthetics. Therefore, it is significant to explore whether the combination of topical anesthesia and intravenous anesthetics could decrease the stress response of endotracheal intubation and keep hemodynamics stable during and after the induction period.

Condition or Disease Intervention/Treatment Phase
  • Procedure: The combined topical anesthesia induction group
N/A

Detailed Description

The routine anesthesia induction strategy for cardiac surgery is to decrease stress response during endotracheal intubation by using large doses of opioids. However, high doses of opioids often leads to persistent and recurrent hypotension in patients from the anesthesia induction period to the beginning of the surgery. Patients scheduled to accept cardiac surgery often have severe concomitant disease. Hemodynamic fluctuation might lead to disastrous events. Anesthesia induction for such patients should not only provide adequate depth of anesthesia to decrease the stress response of endotracheal intubation, but also make hemodynamics stable after tracheal intubation.

Study Design

Study Type:
Interventional
Actual Enrollment :
96 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Effect of Topical Anesthesia Combined With Intravenous Induction on Hemodynamics During the Induction Period in Patients Undergo Cardiac Surgery: a Randomized Controlled Study
Actual Study Start Date :
Mar 5, 2021
Actual Primary Completion Date :
Apr 27, 2021
Actual Study Completion Date :
Apr 27, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: The combined topical anesthesia induction group

The superior glottic mucosa would be anesthetized 3 times with a vaporizer before intravenous anesthesia. After the intravenous induction, a catheter would be inserted to provide the subglottic anesthesia,3-5ml 2% lidocaine would be used for supraglottic anesthesia, and 3ml 1% tetracaine would be used for subglottic anesthesia.

Procedure: The combined topical anesthesia induction group
The superior glottic mucosa would be anesthetized 3 times with a vaporizer before intravenous anesthesia. After the intravenous induction, a catheter would be inserted to provide the subglottic anesthesia,3-5ml 2% lidocaine would be used for supraglottic anesthesia, and 3ml 1% tetracaine would be used for subglottic anesthesia.

No Intervention: The routine induction group

The superior glottic mucosa would be anesthetized 3 times with a vaporizer before intravenous anesthesia. After the intravenous induction, a catheter would be inserted to provide the subglottic anesthesia.In the routine induction group,all procedures will be the same as those of the topical anesthesia group, The drug will be replaced with constant volume saline.

Outcome Measures

Primary Outcome Measures

  1. The area under the curve of baseline blood pressure [From the beginning of general anesthesia induction(T1) to the surgery beginning(T2). T1 is when induction drug (midazolam) is administered. T2 is defined as the time of the skin incision. It will take up to 1hour or 2hours.]

    The area under the curve (AUC) of blood pressure below baseline from the beginning of general anesthesia induction to the surgery beginning.

Secondary Outcome Measures

  1. The frequency and types of vasoactive drugs used. [From the beginning of general anesthesia induction(T1) to the surgery beginning(T2). T1 is when induction drug (midazolam) is administered. T2 is defined as the time of the skin incision. It will take up to 1hour or 2hours.]

    The frequency and types of vasoactive drugs used ,such as the use of norepinephrine and dopamine.

  2. The incidence of arrhythmias. [From the beginning of general anesthesia induction(T1) to the surgery beginning(T2). T1 is when induction drug (midazolam) is administered. T2 is defined as the time of the skin incision. It will take up to 1hour or 2hours.]

    The incidence of arrhythmias, such as atrioventricular block, atrial fibrillation, ventricular tachycardia and so on.

  3. cardiac systolic function:Left Ventricular Ejection Fraction (LVEF) [Preoperative, intraoperative]

    Left ventricular ejection fraction is a reliable indicator of left ventricular systolic function. left ventricular ejection fraction (LVEF) (﹪)= stroke output (SV)/ left ventricular end-diastolic volume (LEDV)×100﹪

  4. cardiac diastolic function:E/E' (the ratio of E peak and E') or E/A :(the ratio of E peak and A peak) [Preoperative, intraoperative]

    E/A ratio, one of the main indicators for evaluating diastolic function, indicated normal diastolic function when E/A >1, and decreased diastolic function when E/A < 1.

  5. cardiac output monitoring indicator: CO(cardiac output) [Intraoperative]

    CO=Stroke Output (SV)× Heart Rate (HR).The relevant parameters are obtained by the cardiac output monitor which produced by Edwards Lifesciences.

  6. cardiac output monitoring indicator: SVV(stroke volume variation) [Intraoperative]

    The relevant parameters are obtained by the cardiac output monitor which produced by Edwards Lifesciences.

  7. cardiac output monitoring indicator: CI(cardiac index) [Intraoperative]

    CI=CO/ Body Surface Area (BSA).The relevant parameters are obtained by the cardiac output monitor which produced by Edwards Lifesciences.

  8. cardiac output monitoring indicator: SVR (systemic vascular resistance) [Intraoperative]

    SVR=60×(MAP-CVP)/CO. MAP: mean arterial pressure. CVP: central venous pressure.The relevant parameters are obtained by the cardiac output monitor which produced by Edwards Lifesciences.

  9. The number of patients with postoperative hoarseness. [Three days after the surgery]

    Hoarseness was classified as mild, moderate and severe according to the severity.

  10. The number of patients with postoperative sore throat. [Three days after the surgery]

    Sore throats can be evaluated using the Numeric Pain Scale (NRS) pain numerical score.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Patients scheduled to accept elective /major cardiac surgery;

  2. Patients older than 18 years and younger than 85 years;

  3. Patients of The American Society of Anesthesiologists ( ASA )Ⅱ - Ⅳ level grade;

  4. Patients signed the informed consent form for the clinical study;

Exclusion Criteria:
  1. Patients cannot cooperate to topical anesthesia;

  2. Patients with a left cardiac assist device prior to surgery;

  3. Patients with aortic dissection;

  4. Patients with Intra Aortic Balloon Pump (IABP) prior to surgery;

  5. Patients treated with Extracorporeal Membrane Oxygenation (ECMO) prior to surgery;

  6. Patients with difficult airway;

  7. Patients with high sensitivity and hypersensitivity to lidocaine and tetracaine;

  8. Patients with atrioventricular block;

  9. Hemoglobin(Hb)<80g/L;

  10. Patients who have participated in other clinical studies during the last 3 months;

Contacts and Locations

Locations

Site City State Country Postal Code
1 Meng-Lv Jinan Shandong China 250000

Sponsors and Collaborators

  • Qianfoshan Hospital

Investigators

  • Principal Investigator: Meng Lv, doctor, Qianfoshan Hospital, The First Hospital affiliated of Shandong First Medical University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Lili Cao, Professor, Qianfoshan Hospital
ClinicalTrials.gov Identifier:
NCT04744480
Other Study ID Numbers:
  • TACTICS
First Posted:
Feb 9, 2021
Last Update Posted:
Jun 2, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Lili Cao, Professor, Qianfoshan Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 2, 2022